Navigation Links
Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement For Plasmid DNA Production

SAN DIEGO, Feb. 26, 2013 /PRNewswire/ -- Althea Technologies, Inc., a leading provider of biopharmaceutical development and manufacturing services, and Profectus BioSciences Inc, a technology based vaccine company, today announced the signing of a manufacturing supply agreement for plasmid DNA production. Under the agreement, Althea will provide gram-scale quantities of cGMP (current Good Manufacturing Practice) manufactured plasmid DNA expressing IL-12 to assist Profectus Biosciences' ongoing DNA vaccine development efforts, which are supported by a contract from the National Institutes of Health. IL-12 helps prompt an immune response once the DNA enters a cell, which is part of Profectus Biosciences' technology platform designed to overcome the poor delivery and immunogenicity of many DNA vaccines.


"Profectus is very pleased to establish this partnership with Althea for the production of the clinical grade plasmids for our DNA vaccine programs," said John Eldridge , Chief Scientific Officer of Profectus BioSciences. "Althea provides an unmatched combination of state-of-the-art facilities and expertise in this area and we anticipate a long and productive association." 

"We are delighted to be awarded this contract, this project has tremendous potential for treating some of the world's most devastating and challenging diseases" stated Rick Hancock , President and CEO of Althea Technologies. "By establishing this partnership, Althea will be able to leverage our plasmid manufacturing expertise to help advance this DNA vaccines program through the clinic and to the patients who need it."

About Althea Technologies, Inc.
Althea Technologies is a fully integrated, contract development and manufacturing organization located in San Diego, CA providing clinical and commercial product development services. Althea offers cGMP drug product filling in both vials and syringes, and production of microbial-derived recombinant proteins and plasmid DNA. In conjunction with these manufacturing operations, Althea offers comprehensive development services including: upstream and downstream process development, analytical development, lyophilization cycle, complex formulation, product release and ICH-compliant stability testing. Althea's formulation technology platform includes Crystalomics®, a proprietary technology that offers a formulation solution for large molecule products that must be delivered at high concentrations or as sustained release formulations. For more information, visit

About Profectus Biosciences.
Profectus BioSciences, Inc. is a technology based vaccine company devoted to the treatment and prevention of infectious diseases and related cancers, with the goal of reducing morbidity and mortality. Since its inception in 2003, the Company's strategic intent has been to acquire and develop the technologies needed to achieve this goal. The Company has licensed a group of vaccine?based technologies from Wyeth Vaccines (now Pfizer, Inc.) that greatly enhance the immunogenicity of prophylactic and therapeutic vaccines based on a "prime?boost" strategy. This strategy uses the delivery of a best?in?class pDNA vaccine to "prime" the immune system, followed by a first-in-class "boost" with an rVSV vector. Current disease and virus targets include hepatitis C virus (HCV), human papilloma virus (HPV), herpes simplex virus type 2 (HSV?2), human immunodeficiency virus (HIV), Ebola virus, Marburg Virus, the arenaviruses and malaria. The Profectus HIV DNA vaccine program has been supported through the award of a $32 M HIV Vaccine Design and Development Teams (HVDDT) contract (HHSN272200800062C) from the NIH that has supported 60% of the research, development, and manufacturing costs of the multi-antigen HIV vaccine and GENEVAX™ IL-12 programs, while the remainder of the cost has been provided through a contribution-in-kind. Partners and collaborators include Ichor Medical Systems, the Galveston National Laboratory, Yale University, the Institute of Human Virology, the Center for HIV/AIDS Vaccine Immunology, the National Cancer Institute, the NIH Division of AIDS, the Bill and Melinda Gates Foundation, the International AIDS Vaccine Initiative, the PATH Malaria Vaccine Initiative, the HIV Vaccines Trials Network, and the AIDS Clinical Trials Group. More information is available at

SOURCE Althea Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. University of Colorado and Orphan Technologies sign agreement
2. Preclinical study shows potential of new technologies to detect response to cancer therapy earlier
3. LaserLock Technologies Files for Provisional Patent Enabling Mobile Phones with Anti-Counterfeiting Technology
4. Going negative: Stanford scientists explore new technologies that remove atmospheric CO2
5. New modeling approach transforms imaging technologies
6. Life Technologies ayudará a identificar 20.000 restos humanos encontrados en fosas comunes en Libia
7. New supercomputer coming to EMSL this summer, supplied by Atipa Technologies
8. UT Dallas researchers awarded $4.3 million to create next-generation technologies
9. ASU partners with Life Technologies on US DHHS funded project to rapidly assess radiation dose
10. Lyncean Technologies Inc. sells Compact Light Source to Munich biomedical-imaging research center
11. NREL researchers use imaging technologies to solve puzzle of plant architecture
Post Your Comments:
(Date:9/26/2015)... 26th, 2015  Results of a TactioRPM pilot ... today at the Stanford Medicine X Conference. In ... Dashboards, Connected Health Devices and Pharmacogenomics", Roger ... will explain how senior patients equipped with connected ... pharmacist via the TactioRPM remote patient monitoring platform ...
(Date:9/24/2015)... September 24, 2015 ... 2015 Kerv ( ... lanserar idag världens första kontaktlösa betalningsring på ... 77 000 GBP för massproduktion via crowdfunding.  ... ) , Kerv-bärare kan göra ...
(Date:9/10/2015)... -- Report Details Emerging Biological Drugs ... Revenue Prospects to Help You Stay Ahead ... drug classes? Get the latest technological and commercial ... data and industry knowledge, benefitting your influence. And ... sales predictions. Visiongain,s new study reveals what,s ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... Research and Markets( ) has announced the addition ... Morphogenetic Protein Growth Factor Therapy - 16 Countries (2011-2021)" ... --> Bone morphogenetic proteins (BMPs) are ... a fracture. In nature, these proteins have a critical ... skeleton. There are twenty different BMPs that have been ...
(Date:10/13/2015)... October 13, 2015 " Microbiology Culture ... 2015 - 2023 " , the global microbiology ... anticipated to reach US$7.59 bn by 2023, expanding at a CAGR ... --> " Microbiology Culture Market - Global Industry Analysis, ... , the global microbiology culture market was valued at ...
(Date:10/13/2015)... ... October 13, 2015 , ... AxioMx Inc. ... it has received a Phase I Small Business Innovative Research (SBIR) grant (1R43GM112204-01A1). ... General Medical Sciences (NIGMS), will fund the development of a technique to rapidly ...
(Date:10/13/2015)... 13, 2015      Q BioMed ... has entered into a strategic relationship with Wombat Capital, ... Paris, France based strategic and ... --> This collaborative arrangement gives Q BioMed and ... team as well as long established pharmaceutical industry relationships. ...
Breaking Biology Technology: